TARRYTOWN, N.Y. and PARIS, July 2, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab ...

"We await results of the ongoing Phase 3 trial to learn more about COVID-19, and better understand whether some patients may benefit from Kevzara treatment." Year-to-date, Regeneron's stock has ...

In the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs ...

Sanofi and Regeneron just added another building block to a nascent immunology franchise expected to bring in $5 billion or more by 2022. But to get there, their new Kevzara will have to go up ...

Regeneron Pharmaceuticals and Sanofi said today they have launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara ® (sarilumab) as a treatment for ...

Sanofi and Regeneron Pharmaceuticals said today they will narrow the Phase III portion of their trial assessing the marketed arthritis drug Kevzara ® (sarilumab) as a COVID-19 treatment after ...

and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients ...

Sanofi SNY and its collaboration partner, Regeneron Pharmaceuticals REGN intend to restructure their antibody collaboration into a royalty-based agreement for Kevzara (sarilumab) and Praluent ...

A day earlier, Regeneron (ticker: REGN) said it had started trials with its existing arthritis drug, Kevzara, which might prove useful in treating lung inflammation in Covid-19 patients ...

We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs. Dupixent’s ...

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients PARIS and TARRYTOWN, N.Y. - July 2, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Yancopoulos, M.D., Ph.D., Regeneron Co-Founder, President and Chief Scientific Officer. "Emerging evidence with Kevzara and other repurposed drugs in the COVID-19 crisis highlight the challenges ...